Current status and prospects of viral vector-based gene therapy to treat kidney diseases

Louise Medaer,Koenraad Veys,Rik Gijsbers
DOI: https://doi.org/10.1089/hum.2023.184
2024-02-23
Human Gene Therapy
Abstract:Inherited kidney diseases (IKD) are among the leading causes of chronic kidney disease (CKD), reducing the quality of life, and resulting in substantial socio-economic impact. The advent of early genetic testing and the growing understanding of the molecular basis and pathophysiology of these disorders have opened avenues for novel treatment strategies. Viral vector-based gene therapies have evolved from experimental treatments for rare diseases to potent platforms that carry the intrinsic potential to provide a cure with a single application. Several gene therapy products have reached the market and numbers are only expected to increase. Still, none target inherited kidney diseases. Gene transfer to the kidney has lagged when compared to other tissue-directed therapies like hepatic, neuromuscular, and ocular tissues. Systemic delivery of genetic information to tackle kidney disease is challenging. The pharma industry is taking steps to take on kidney disease and to translate the current research into the therapeutic arena. In this review we provide an overview of the current viral vector-based approaches and their potential. We discuss advances in platforms and injection routes that have been explored to enhance gene delivery towards kidney cells in animal models, and how these can fuel the development of viable gene therapy products for humans.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?